Cite
HARVARD Citation
Ella, R. et al. (2021). Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 398 (10317), pp. 2173-2184. [Online].